Literature DB >> 8363378

Bioequivalence of oral and intravenous ofloxacin after multiple-dose administration to healthy male volunteers.

S C Flor1, M C Rogge, A T Chow.   

Abstract

The bioequivalence of oral and intravenous ofloxacin was investigated after the administration of multiple doses of 400 mg every 12 h to 20 healthy male volunteers in a randomized, crossover, open-label study. Ofloxacin concentrations in plasma were evaluated after 4 days of oral or intravenous (1-h infusion) dosing with a 3-day wash-out period between regimens. As expected, delivery to the systemic circulation took slightly longer after the oral dosing (time to maximum concentration of drug in serum of 1.7 h) relative to the 1-h intravenous infusion, but the systemic availabilities of ofloxacin by the two routes of administration were equivalent (area under the concentration-time curve from 0 to 12 h ratio of 95%). Since previous studies have not demonstrated any change in the bioavailability of ofloxacin in infectious disease patients, this study supports the interchangeability of these dosing regimens.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8363378      PMCID: PMC187996          DOI: 10.1128/AAC.37.7.1468

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Pharmacodynamic evaluation of ofloxacin and trimethoprim-sulfamethoxazole in vaginal fluid of women treated for acute cystitis.

Authors:  T A Tartaglione; C R Johnson; P Brust; K Opheim; T M Hooton; W E Stamm
Journal:  Antimicrob Agents Chemother       Date:  1988-11       Impact factor: 5.191

2.  In vitro activity and concentrations in serum, urine, prostatic secretion and adenoma tissue of ofloxacin in urological patients.

Authors:  K G Naber; D Adam; F Kees
Journal:  Drugs       Date:  1987       Impact factor: 9.546

3.  A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability.

Authors:  D J Schuirmann
Journal:  J Pharmacokinet Biopharm       Date:  1987-12

4.  Comparative pharmacokinetics of ciprofloxacin and ofloxacin in cystic fibrosis patients.

Authors:  S S Pedersen; T Jensen; E F Hvidberg
Journal:  J Antimicrob Chemother       Date:  1987-10       Impact factor: 5.790

5.  Pharmacokinetics of ofloxacin after parenteral and oral administration.

Authors:  H Lode; G Höffken; P Olschewski; B Sievers; A Kirch; K Borner; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

6.  Noncompartmental determination of the steady-state volume of distribution during multiple dosing.

Authors:  I L Smith; J J Schentag
Journal:  J Pharm Sci       Date:  1984-02       Impact factor: 3.534

7.  Oral pharmacokinetics and ascitic fluid penetration of ofloxacin in cirrhosis.

Authors:  C Silvain; S Bouquet; J P Breux; B Becq-Giraudon; M Beauchant
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

8.  Bioavailability and pharmacokinetics of ofloxacin in healthy volunteers.

Authors:  J H Yuk; C H Nightingale; R Quintiliani; K R Sweeney
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

9.  Safety and pharmacokinetics of multiple doses of intravenous ofloxacin in healthy volunteers.

Authors:  D R Guay; J A Opsahl; F G McMahon; R Vargas; G R Matzke; S Flor
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

10.  Ofloxacin penetration into tuberculous pleural effusion.

Authors:  W W Yew; J Lee; C Y Chan; S W Cheung; P C Wong; S Y Kwan
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

View more
  6 in total

1.  Pharmacokinetics and safety of oral levofloxacin in human immunodeficiency virus-infected individuals receiving concomitant zidovudine.

Authors:  S C Chien; A T Chow; M C Rogge; R R Williams; C W Hendrix
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

2.  Application of an in vitro infection model and simulation for reevaluation of fluoroquinolone breakpoints for Salmonella enterica serotype typhi.

Authors:  Brent M Booker; Patrick F Smith; Alan Forrest; Julie Bullock; Pamela Kelchlin; Sujata M Bhavnani; Ronald N Jones; Paul G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

Review 3.  Commonly used antibacterial and antifungal agents for hospitalised paediatric patients: implications for therapy with an emphasis on clinical pharmacokinetics.

Authors:  J Singh; B Burr; D Stringham; A Arrieta
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

4.  Pharmacokinetics and safety of levofloxacin in patients with human immunodeficiency virus infection.

Authors:  S D Goodwin; H A Gallis; A T Chow; F A Wong; S C Flor; J A Bartlett
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

Review 5.  Ofloxacin. A reappraisal of its use in the management of genitourinary tract infections.

Authors:  S V Onrust; H M Lamb; J A Balfour
Journal:  Drugs       Date:  1998-11       Impact factor: 9.546

6.  In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis.

Authors:  B JI; N Lounis; C Truffot-Pernot; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.